Table 1.

Biologics and targets for atopic disorders

Biologic	Target	Indication(s)
Omalizumab (Xolair)	Anti-IgE	Moderate-to-severe persistent atopic asthma in patients ages ≥ 6 y inadequately controlled by inhaled corticosteroids; chronic idiopathic urticaria in patients ages ≥ 12 y inadequately controlled by H1 antihistamine treatment; currently in phase III clinical trial evaluating omalizumab as monotherapy and as adjunct therapy to OIT in subjects with multiple food allergies (NCT03881696)
Mepolizumab (Nucala)	Anti-IL-5	Severe eosinophilic asthma in patients ages ≥ 12 y as add-on maintenance treatment
Reslizumab (Cinqair)	Anti-IL-5	Severe eosinophilic asthma in patients ages ≥ 18 y as add-on maintenance treatment
Benralizumab (Fasenra)	Anti-IL-5R	Severe eosinophilic asthma in patients ages ≥ 12 y as add-on maintenance treatment
Dupilumab (Dupixent)	Anti-IL-4Rα	Currently in four clinical trials for food allergy: (a) dupilumab monotherapy for treating peanut allergy (NCT03793608), (b) dupilumab as adjunctive therapy with OIT for peanut allergy (NCT03682770), (c) dupilumab as adjunctive therapy with OIT for multiple food allergies (NCT03679676), and (d) dupilumab as an adjunctive therapy with OIT for cow's milk allergy (NCT04148352)
Etokimab	Anti-IL-33	Completed phase IIa clinical trial for adults with peanut allergy (NCT02920021)

IgE = Immunoglobulin E; IL = interleukin; IL-4Rα = IL-4 receptor α.